Abstract: The present disclosure relates to an electrolyte injection system, and the electrolyte injection system is a system for injecting an electrolyte solution into a pouch in which an electrode assembly is embedded, the electrolyte injection system comprising: an injection pipe for injecting an electrolyte solution; an electrolyte solution supply portion supplying an electrolyte solution; and a manifold portion connecting an injection pipe and an electrolyte solution supply portion to prevent a reverse flow of the electrolyte solution and ensure precision of injection amount so that a large amount of electrolyte solution may be accurately and rapidly injected.

Abstract: A color conversion substrate and a display device are provided. The color conversion substrate includes a base substrate, a first color filter and a second color filter disposed on a surface of the base substrate, a first partition layer disposed between the first color filter and the second color filter, a second partition layer disposed on the first partition layer, a first wavelength conversion pattern disposed on the first color filter and a second wavelength conversion pattern disposed on the second color filter, wherein the first partition layer includes a first lower surface disposed on the first color filter and a second lower surface disposed on the second color filter.

Abstract: The present disclosure relates to a method for carrying out dose delivery quality assurance for high-precision radiation treatment, in which parameters affecting a pass rate of dose delivery quality assurance can be derived through regression analysis, which is a known statistical analysis method, and a pass rate prediction model capable of predicting each parameter and the pass rate of dose delivery quality assurance can be derived, and accordingly, it can be predicted in advance whether dose delivery quality assurance will be passed according to the parameters through the above prediction model, without repeatedly carrying out dose delivery quality assurance according to a patient's treatment plan, and as a result, the efficiency of dose delivery quality assurance can be enhanced, and the time or capacity required for such quality assurance is reduced, such that radiation treatment for an actual patient can be quickly and precisely carried out.

Abstract: Disclosed is a pharmaceutical composition comprising eupatilin as an active ingredient for suppressing osteoclast differentiation, bone metastasis, and osteolysis and for preventing or treating periodontitis. Found to effectively inhibit the differentiation of osteoclast progenitors into osteoclasts and the fusion of mononucleated osteoclasts into multinucleated osteoclasts, and reduce the bone resorption of W multinucleated osteoclasts, Eupatilin is capable of effectively suppressing bone metastasis and osteolysis and may be used to prevent or treat periodontitis.

Abstract: Disclosed is a composition for inducing the differentiation of osteoclasts containing progranulin as an active ingredient, or a composition for the prevention or treatment of osteoporosis containing a progranulin inhibitor as an active ingredient, wherein progranulin functions as an RANK-dependent cell-communication factor and as a mediator in osteoporosis through inflammation, and exists at a remarkably high concentration, compared to a control, in the serum of prostate cancer patients, osteoporosis patients, and bedridden patients with low bone mineral density, whereby the progranulin can be used as an osteoclast differentiation factor and as a biomarker for osteoporosis or metastatic prostate cancer.

Abstract: Provided is an injectable drug carrier including a non-toxic Layered Double Hydroxide (LDH) and pharmaceutically acceptable excipients. Provided is also a method of preparing the injectable drug carrier, the method including: synthesizing LDH with various compositions and controlling the size and shape of the LDH at a level that the LDH has no adverse effect in vivo. A solution obtained by dispersing the LDH in a solvent is injected in vivo. According to the method, nano-size LDH that does not affect a blood vessel in vivo can be synthesized. The LDH thus synthesized has no adverse effect in vivo even at a concentration of 400 mg/kg, and thus can contribute to establishment of a drug delivery system capable of improving the delivery efficiency of a specific drug.

Abstract: A resistive memory device capable of implementing a multi-level cell (MLC) and a fabrication method thereof are provided. The resistive memory device includes a lower electrode connected to a switching device and including a first node and a second node formed on a top thereof to be spaced at a fixed interval, a phase-change material pattern formed on the first node and the second node, an upper electrode formed on the phase-change material pattern, a conductive material layer formed on a top and outer sidewall of the upper electrode, a first contact plug formed on one edge of the upper electrode to be connected to the upper electrode and the conductive material layer, and a second contact plug formed on the other edge of the upper electrode to be connected to the upper electrode and the conductive material layer.

Abstract: A resistive memory device capable of implementing a multi-level cell (MLC) and a fabrication method thereof are provided. The resistive memory device includes a lower electrode connected to a switching device and including a first node and a second node formed on a top thereof to be spaced at a fixed interval, a phase-change material pattern formed on the first node and the second node, an upper electrode formed on the phase-change material pattern, a conductive material layer formed on a top and outer sidewall of the upper electrode, a first contact plug formed on one edge of the upper electrode to be connected to the upper electrode and the conductive material layer, and a second contact plug formed on the other edge of the upper electrode to be connected to the upper electrode and the conductive material layer.

Abstract: A resistive memory device capable of implementing a multi-level cell (MLC) and a fabrication method thereof are provided. The resistive memory device includes a lower electrode connected to a switching device and including a first node and a second node formed on a top thereof to be spaced at a fixed interval, a phase-change material pattern formed on the first node and the second node, an upper electrode formed on the phase-change material pattern, a conductive material layer formed on a top and outer sidewall of the upper electrode, a first contact plug formed on one edge of the upper electrode to be connected to the upper electrode and the conductive material layer, and a second contact plug formed on the other edge of the upper electrode to be connected to the upper electrode and the conductive material layer.

Abstract: A phase-change random access memory device includes a semiconductor substrate, an interlayer dielectric layer formed over the semiconductor substrate and having contact holes defined therein, metal contacts formed in the contact holes, an ohmic contact layer formed over the metal contacts and having recesses defined therein, and switching elements formed over the recesses of the ohmic contact layer.

Abstract: A resistive memory device capable of implementing a multi-level cell (MLC) and a fabrication method thereof are provided. The resistive memory device includes a lower electrode connected to a switching device and including a first node and a second node formed on a top thereof to be spaced at a fixed interval, a phase-change material pattern formed on the first node and the second node, an upper electrode formed on the phase-change material pattern, a conductive material layer formed on a top and outer sidewall of the upper electrode, a first contact plug formed on one edge of the upper electrode to be connected to the upper electrode and the conductive material layer, and a second contact plug formed on the other edge of the upper electrode to be connected to the upper electrode and the conductive material layer.

Abstract: The present invention provides a liquid crystal photoalignment agent that includes a compound selected from the group consisting of a polyamic acid having a predetermined chemical formula, a polyimide polymer having a predetermined chemical formula, and a combination thereof, and a polyimide photopolymer. The liquid crystal photoalignment agent shows a long life-span, stably maintains a pretilt angle, and shows improved after-image characteristics, liquid crystal alignment properties, and chemical resistance.

Abstract: A phase-change random access memory device includes a semiconductor substrate, an interlayer dielectric layer formed over the semiconductor substrate and having contact holes defined therein, metal contacts formed in the contact holes, an ohmic contact layer formed over the metal contacts and having recesses defined therein, and switching elements formed over the recesses of the ohmic contact layer.

Abstract: Provided is an injectable drug carrier including a non-toxic Layered Double Hydroxide (LDH) and pharmaceutically acceptable excipients. Provided is also a method of preparing the injectable drug carrier, the method including: synthesizing LDH with various compositions and controlling the size and shape of the LDH at a level that the LDH has no adverse effect in vivo. A solution obtained by dispersing the LDH in a solvent is injected in vivo. According to the method, nano-size LDH that does not affect a blood vessel in vivo can be synthesized. The LDH thus synthesized has no adverse effect in vivo even at a concentration of 400 mg/kg, and thus can contribute to establishment of a drug delivery system capable of improving the delivery efficiency of a specific drug.

Abstract: One embodiment of the present invention provides a liquid crystal photo-alignment agent that includes a polyamic acid copolymer including a repeating unit having the following Formula 1 and a repeating unit having the following Formula 2; a polyimide copolymer including a repeating unit having the following Formula 3 and a repeating unit having the following Formula 4; or a combination thereof: wherein the definition of R1 to R8 are the same as in the specification. The liquid crystal photo-alignment agent can have improved liquid crystal alignment properties, electrical characteristics such as voltage holding ratio, pretilt angle, residual DC, and the like, printability, cleaning stability, and spot stability, and is capable of unidirectionally aligning liquid crystals by ultraviolet (UV) exposure.

Abstract: 3,4-Dicarboxy-1,2,3,4-tetrahydro-6-t-butyl-1-naphthalene-succinic dianhydride is provided. The tetracarboxylic dianhydride is represented by Formula 1, which is described in the specification. Further provided is a liquid crystal aligning agent comprising a polyimide prepared using the tetracarboxylic dianhydride and a solvent. Further provided is a liquid crystal alignment layer formed using the liquid crystal aligning agent. The liquid crystal alignment layer exhibits excellent electro-optical properties and good processability in terms of printability.

Abstract: Disclosed herein is a novel functional diamine compound having a dendron structure, polyamic acid which is produced using functional diamine, aromatic cyclic diamine, aliphatic cyclic acid dianhydride, and aromatic cyclic acid dianhydride, polyimide which is produced by imidizing polyamic acid, and an LC alignment film produced using polyimide. Even if the diamine compound is used in a small amount, it is possible to realize a high pretilt angle, thus the pretilt angle is easily controlled. Therefore, it can be used to produce an LC alignment film using a twisted nematic (TN) mode, in which the pretilt angle of liquid crystal is low, and a vertically aligned (VA) mode, which requires a high pretilt angle of about 90°.

Abstract: The present invention provides a liquid crystal photoalignment agent that includes a compound selected from the group consisting of a polyamic acid having a predetermined chemical formula, a polyimide polymer having a predetermined chemical formula, and a combination thereof, and a polyimide photopolymer. The liquid crystal photoalignment agent shows a long life-span, stably maintains a pretilt angle, and shows improved after-image characteristics, liquid crystal alignment properties, and chemical resistance.

Abstract: Disclosed herein is a novel functional diamine compound having a dendron structure, polyamic acid which is produced using functional diamine, aromatic cyclic diamine, aliphatic cyclic acid dianhydride, and aromatic cyclic acid dianhydride, polyimide which is produced by imidizing polyamic acid, and an LC alignment film produced using polyimide. Even if the diamine compound is used in a small amount, it is possible to realize a high pretilt angle, thus the pretilt angle is easily controlled. Therefore, it can be used to produce an LC alignment film using a twisted nematic (TN) mode, in which the pretilt angle of liquid crystal is low, and a vertically aligned (VA) mode, which requires a high pretilt angle of about 90°.

Abstract: The liquid crystal alignment agent according to one embodiment of the present invention includes a soluble polyimide polymer of Formula 1 and a solvent. The soluble polyimide polymer has a number average molecular weight of about 10,000 to 500,000 g/mol, and a polydispersity of about 1.2 to about 1.75. The liquid crystal alignment agent can have good printability on a substrate, and thereby can provide a liquid crystal alignment film that can have excellent film uniformity, even though its predrying temperature is varied.